Ajuts a la recerca

EFSD and Merck Sharp & Dohme

Organisme

EFSD and Merck Sharp & Dohme (MSD)- European Research Programme on Novel Therapies for Type 2 Diabetes
 

Objecte

Background

The European Foundation for the Study of Diabetes (EFSD) was created by the European Association for the Study of Diabetes (EASD) to provide funding initiatives in all areas of diabetes research. The aims of EFSD are to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge and to facilitate its application.

Merck & Co., Inc is a global, research-driven pharmaceutical company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. Merck Sharpe & Dohme, or MSD, is the name Merck uses for conducting its business in all other countries outside the United States and Canada.

Programme and Research Focus

EFSD and MSD have established a European Research Programme for preclinical/translational research on novel therapies to encourage the identification of new targets for the treatment of type 2 diabetes.

To achieve the goals and objectives of this Programme, EFSD and MSDinvite applications by issuing this "Request for Applications" (RFA), which indicates joint funding as well as areas of research emphasis.

The EFSD/MSD European Research Programme on Novel Therapies for Type 2 Diabetes is intended to stimulate and accelerate European research focusing on the identification and molecular understanding of new targets for the treatment of type 2 diabetes.

Proposals may include but are not limited to:
Mechanisms to induce “browning of adipose tissue”
Novel targets for improving skeletal muscle or adipose tissue insulin resistance
Bile acid biology as it relates to metabolic disease. This includes actions relating to glucose metabolism, lipid metabolism, energy balance and related diseases including diabetes, atherosclerosis and obesity
Lipid metabolism as it relates to insulin action
Mechanisms of glucose-dependent insulin and glucagon secretion
 

Termini oficial

Deadline for submission of applications: 15 March 2014

Termini IISPV

Declaration of interest: IISPV's deadline: February 28th, 2014 (europa@iispv.cat) Full proposal: IISPV's deadline: March 11, 2014

Pujar